Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA
暂无分享,去创建一个
Ning Liu | Zhihong Zhu | M. Rusckowski | D. Hnatowich | Yu-min Zhang | Ning Liu | Yu-Min Zhang | Zhi-Hong Zhu | Mary Rusckowski | Donald J. Hnatowich
[1] M. Rusckowski,et al. Technetium-99m antibodies labeled with MAG3 and SHNH: an in vitro and animal in vivo comparison. , 1996, Nuclear medicine and biology.
[2] D. Hnatowich. Antisense and nuclear medicine. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] Bernard Bendriem,et al. In vivo imaging of oligonucleotides with positron emission tomography , 1998, Nature Medicine.
[4] R. Karlsson,et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. , 1991, BioTechniques.
[5] C. Cantor,et al. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice. , 1996, The Journal of pharmacology and experimental therapeutics.
[6] M. Rusckowski,et al. Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm , 2001, Nuclear medicine communications.
[7] R. L. Childs,et al. Optimum conditions for labeling of DTPA-coupled antibodies with technetium-99m. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] R. Wagner. Gene inhibition using antisense oligodeoxynucleotides , 1994, Nature.
[9] V. Vlassov,et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[10] G. Sfakianakis,et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] R. L. Childs,et al. Radioactive labeling of antibody: a simple and efficient method. , 1983, Science.
[12] S. Crooke,et al. Molecular mechanisms of antisense drugs: RNase H. , 1998, Antisense & nucleic acid drug development.
[13] D. Hnatowich. Changing focus: applying antisense to nuclear medicine imaging. , 1999, Molecular medicine today.
[14] Magnus Malmqvist,et al. Biospecific interaction analysis using biosensor technology , 1993, Nature.
[15] S. Crooke. Progress toward oligonucleotide therapeutics: pharmacodynamic properties , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] A. Fischman,et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] P. Winnard,et al. Can a cysteine challenge assay predict the in vivo behavior of 99mTc-labeled antibodies? , 1994, Nuclear medicine and biology.